Key result
Mast cell activation disease has ~17% prevalence and frequently presents with cardiovascular manifestations requiring tailored therapy.
Why the study?
Cardiologists and angiologists frequently encounter mast cell activation disease given its estimated prevalence of up to 17%, but often fail to recognize it.
Highlights the importance for cardiologists and angiologists to recognize and understand the cardiovascular manifestations of mast cell activation disease.
May warrant consideration in unexplained cardiovascular presentations; leaves open whether targeted therapy improves outcomes.
Mast cell activation disease is a genetic disease entity characterized by a very pronounced clinical symptomatology with potential manifestations in virtually every organ and tissue. These arise from the inappropriate release of mast cell mediators and the accumulation of both morphologically normal and mutated mast cells. Owing to the high prevalence of the disease-estimated to be up to 17%-cardiologists and angiologists are frequently confronted with mast cell activation disease in their daily clinical practice, often without recognizing it. Therefore, every cardiologist and angiologist should possess basic knowledge about this disease and be aware of its cardiovascular challenges. This review summarizes the current state of knowledge on this highly complex disease, with a particular focus on the cardiovascular aspects.
No takes yet. Share an insight, caveat, or question.
Taumann et al. (2025) conducted a review in Mast cell activation disease. Mast cell activation disease, with an estimated prevalence up to 17%, frequently presents with cardiovascular manifestations such as dysrhythmias, heart failure, and hypotension, requiring tailored therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: